The American Society of Clinical Oncology guidelines recommend monitoring the levels of troponins and BNP/NT-proBNP in patients receiving anthracyclines at risk for cardiotoxicity during and after cancer treatment [36]. The gene discussed is NPPB; the disease is cancer.